Title |
Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]
|
---|---|
Published in |
BMC Neurology, September 2011
|
DOI | 10.1186/1471-2377-11-111 |
Pubmed ID | |
Authors |
Ammar Al-Chalabi, Pamela J Shaw, Carolyn A Young, Karen E Morrison, Caroline Murphy, Marie Thornhill, Joanna Kelly, I Nicholas Steen, P Nigel Leigh |
Abstract |
Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disorder characterised by loss of motor neurons leading to severe weakness and death from respiratory failure within 3-5 years. Riluzole prolongs survival in ALS. A published report has suggested a dramatic effect of lithium carbonate on survival. 44 patients were studied, with 16 randomly selected to take LiCO3 and riluzole and 28 allocated to take riluzole alone. In the group treated with lithium, no patients had died (i.e., 100% survival) at the end of the study (15 months from entry), compared to 71% surviving in the riluzole-only group. Although the trial can be criticised on several grounds, there is a substantial rationale from other laboratory studies that lithium is worth investigating therapeutically in amyotrophic lateral sclerosis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 104 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 22 | 21% |
Researcher | 20 | 19% |
Student > Bachelor | 14 | 13% |
Student > Ph. D. Student | 7 | 7% |
Unspecified | 6 | 6% |
Other | 22 | 21% |
Unknown | 16 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 32% |
Psychology | 18 | 17% |
Unspecified | 6 | 6% |
Neuroscience | 5 | 5% |
Agricultural and Biological Sciences | 5 | 5% |
Other | 16 | 15% |
Unknown | 23 | 21% |